Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications.
OBJECTIVE: To determine whether prophylactic, low dose controlled-release aspirin improves outcome for pregnant women and their babies in Barbados. DESIGN: Randomised placebo-controlled trial. SETTING: The Queen Elizabeth Hospital, Barbados. POPULATION: All women attending antenatal clinics between...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
1998
|
| _version_ | 1797103563555471360 |
|---|---|
| author | Rotchell, Y Cruickshank, J Gay, M Griffiths, J Stewart, A Farrell, B Ayers, S Hennis, A Grant, A Duley, L Collins, R |
| author_facet | Rotchell, Y Cruickshank, J Gay, M Griffiths, J Stewart, A Farrell, B Ayers, S Hennis, A Grant, A Duley, L Collins, R |
| author_sort | Rotchell, Y |
| collection | OXFORD |
| description | OBJECTIVE: To determine whether prophylactic, low dose controlled-release aspirin improves outcome for pregnant women and their babies in Barbados. DESIGN: Randomised placebo-controlled trial. SETTING: The Queen Elizabeth Hospital, Barbados. POPULATION: All women attending antenatal clinics between 12 and 32 weeks of gestation were eligible, if without specific contraindications to aspirin and unlikely to deliver immediately. METHODS: Randomisation was computer-generated in the antenatal clinic; 1822 women were allocated to receive 75 mg controlled-release aspirin and 1825 matching placebo. MAIN OUTCOME MEASURES: Proteinuric pre-eclampsia, other pregnancy-induced hypertension, pregnancy duration, birthweight, stillbirths and neonatal deaths, major neonatal events. RESULTS: All but three women from each group were followed up successfully. Forty-four percent were primigravid, and 8% had previous obstetric complications. There were no significant differences between the allocated treatment groups in the incidence of proteinuric pre-eclampsia (40 [2.2%] of those allocated aspirin, compared with 46 [2.5%] allocated placebo), of preterm delivery (255 [14.0%] vs 270 [14.8%]), of birthweight < 1500 g (32 [1.7%] vs 33 [1.8%]) or of stillbirth and neonatal death (44 [2.4%] vs 38 [2.1%]). Aspirin was not associated with excess risk of maternal or fetal bleeding. CONCLUSIONS: The results of this study in Barbados do not support the routine use of low dose aspirin for prevention of pre-eclampsia or its complications, confirming results of previous large trials in other settings. |
| first_indexed | 2024-03-07T06:21:52Z |
| format | Conference item |
| id | oxford-uuid:f2fa75f9-f31d-4f4f-87a3-a9e8e92d4587 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T06:21:52Z |
| publishDate | 1998 |
| record_format | dspace |
| spelling | oxford-uuid:f2fa75f9-f31d-4f4f-87a3-a9e8e92d45872022-03-27T12:08:18ZBarbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications.Conference itemhttp://purl.org/coar/resource_type/c_5794uuid:f2fa75f9-f31d-4f4f-87a3-a9e8e92d4587Symplectic Elements at Oxford1998Rotchell, YCruickshank, JGay, MGriffiths, JStewart, AFarrell, BAyers, SHennis, AGrant, ADuley, LCollins, R OBJECTIVE: To determine whether prophylactic, low dose controlled-release aspirin improves outcome for pregnant women and their babies in Barbados. DESIGN: Randomised placebo-controlled trial. SETTING: The Queen Elizabeth Hospital, Barbados. POPULATION: All women attending antenatal clinics between 12 and 32 weeks of gestation were eligible, if without specific contraindications to aspirin and unlikely to deliver immediately. METHODS: Randomisation was computer-generated in the antenatal clinic; 1822 women were allocated to receive 75 mg controlled-release aspirin and 1825 matching placebo. MAIN OUTCOME MEASURES: Proteinuric pre-eclampsia, other pregnancy-induced hypertension, pregnancy duration, birthweight, stillbirths and neonatal deaths, major neonatal events. RESULTS: All but three women from each group were followed up successfully. Forty-four percent were primigravid, and 8% had previous obstetric complications. There were no significant differences between the allocated treatment groups in the incidence of proteinuric pre-eclampsia (40 [2.2%] of those allocated aspirin, compared with 46 [2.5%] allocated placebo), of preterm delivery (255 [14.0%] vs 270 [14.8%]), of birthweight < 1500 g (32 [1.7%] vs 33 [1.8%]) or of stillbirth and neonatal death (44 [2.4%] vs 38 [2.1%]). Aspirin was not associated with excess risk of maternal or fetal bleeding. CONCLUSIONS: The results of this study in Barbados do not support the routine use of low dose aspirin for prevention of pre-eclampsia or its complications, confirming results of previous large trials in other settings. |
| spellingShingle | Rotchell, Y Cruickshank, J Gay, M Griffiths, J Stewart, A Farrell, B Ayers, S Hennis, A Grant, A Duley, L Collins, R Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. |
| title | Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. |
| title_full | Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. |
| title_fullStr | Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. |
| title_full_unstemmed | Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. |
| title_short | Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. |
| title_sort | barbados low dose aspirin study in pregnancy blasp a randomised trial for the prevention of pre eclampsia and its complications |
| work_keys_str_mv | AT rotchelly barbadoslowdoseaspirinstudyinpregnancyblasparandomisedtrialforthepreventionofpreeclampsiaanditscomplications AT cruickshankj barbadoslowdoseaspirinstudyinpregnancyblasparandomisedtrialforthepreventionofpreeclampsiaanditscomplications AT gaym barbadoslowdoseaspirinstudyinpregnancyblasparandomisedtrialforthepreventionofpreeclampsiaanditscomplications AT griffithsj barbadoslowdoseaspirinstudyinpregnancyblasparandomisedtrialforthepreventionofpreeclampsiaanditscomplications AT stewarta barbadoslowdoseaspirinstudyinpregnancyblasparandomisedtrialforthepreventionofpreeclampsiaanditscomplications AT farrellb barbadoslowdoseaspirinstudyinpregnancyblasparandomisedtrialforthepreventionofpreeclampsiaanditscomplications AT ayerss barbadoslowdoseaspirinstudyinpregnancyblasparandomisedtrialforthepreventionofpreeclampsiaanditscomplications AT hennisa barbadoslowdoseaspirinstudyinpregnancyblasparandomisedtrialforthepreventionofpreeclampsiaanditscomplications AT granta barbadoslowdoseaspirinstudyinpregnancyblasparandomisedtrialforthepreventionofpreeclampsiaanditscomplications AT duleyl barbadoslowdoseaspirinstudyinpregnancyblasparandomisedtrialforthepreventionofpreeclampsiaanditscomplications AT collinsr barbadoslowdoseaspirinstudyinpregnancyblasparandomisedtrialforthepreventionofpreeclampsiaanditscomplications |